Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 net income $14.2 million versus $7.3 million loss in 2025
- ➤License revenue $40.0 million, up from $10.0 million year-over-year
- ➤Rinvatercept Phase 2 DMD trial dosed first patient; initial data expected first half 2027
- ➤Cash and equivalents $259.5 million; runway expected into second half of 2028
- ➤KER-206 nominated for further investigation as a bone-remodeling ligand trap
Expert Statements
Jasbir S. Seehra, President and Chief Executive Officer of Keros Therapeutics
“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-β biology to develop potential new treatments for patients”
Jasbir S. Seehra, President and Chief Executive Officer of Keros Therapeutics
“We remain focused on disciplined execution of our strategic priorities as we work to advance our programs and build on the potential of our pipeline.”
* First patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in September 2026 * Nominated KER-206, a novel ligand trap designed to bind select TGF-β ligands to regulate bone remodeling, from nonclinical pipeline for further investigation * Cash runway expected into the second half of 2028 LEXINGTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-β”) family of proteins, today provided a business update and reported financial results for the quarter ended September 30, 2026.
“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-β biology to develop potential new treatments for patients,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “We remain focused on disciplined execution of our strategic priorities as we work to advance our programs and build on the potential of our pipeline.”
Get started
Create a free account to read the full story.